BOC Instruments has announced the launch of a new technology that leverages proprietary eye-tracking technology and cloud-based remote monitoring to deliver “comfortable, engaging, and personalised amblyopia therapy from the comfort of home”.
The treatment, CureSight, is backed by randomised, controlled studies published in top peer-reviewed scientific journals that have shown it is clinically superior to traditional eye patching, with improved patient adherence and satisfaction.
A media release said CureSight trains the visual system to use both eyes simultaneously, while the user watches any streamed video content of choice through treatment glasses.
Using sophisticated algorithms and eye-tracking technology, CureSight blurs the centre of vision of the dominant eye using real-time image processing according to the momentary eye gaze.
This dichoptic presentation encourages the visual system to receive the image’s fine details through the amblyopic eye which results in improved visual acuity. In addition, stereoacuity and 3D perception are developed as the brain learns to work with both eyes simultaneously.
The device is designed to be used at home while the treatment is being remotely monitored by the eyecare professionals via a cloud application.
Those keen to know more can contact BOC Instruments on 1800804331 or on email: sales@bocinstruments.com.au.
More reading
BOC Instruments introduces new Nidek AL-Scan M biometer
VF2000 NEO takes out top prize at ODMA Awards of Excellence
Visual field virtual headset offers new reality
